New schizophrenia drug shows promise in early brain study
NCT ID NCT07626034
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new drug called SIPI6398 in 9 people (healthy volunteers and schizophrenia patients). Researchers use brain scans to see how much of the drug reaches brain receptors linked to schizophrenia. The goal is to find the right dose and check safety, not yet to treat symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIPI6398 tablets
- What this could lead to
- If successful, this could help determine the right dose of SIPI6398 for future trials targeting schizophrenia symptoms.
- What could go wrong
- This is a very small, early-phase study (9 participants) focused on brain activity, not symptom improvement. It may not lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?